Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

M.D. Anderson Cancer Center

36 clinical trials · 36 recruiting · OTHER

M.D. Anderson Cancer Center has 36 clinical trials registered on ClinicalTrials.gov, with 36 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About M.D. Anderson Cancer Center\'s Trial Portfolio

M.D. Anderson Cancer Center is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

36 of M.D. Anderson Cancer Center's 36 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

M.D. Anderson Cancer Center's research footprint spans Melanoma (3 trials), Breast Carcinoma (2), and Breast Cancer (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

is the largest single phase in M.D. Anderson Cancer Center's portfolio at 36% of registered trials. The full phase breakdown appears in the sidebar.

Trials by M.D. Anderson Cancer Center

RECRUITINGNCT05056818

Comparison of Synthetic Mammography Versus Full-Field Digital Mammography in Image Interpretation and Performance...

This study compares synthetic mammography to full-field digital mammography in image interpretation and performance metrics. Digital breast tomosynthesis (DBT) has previously been...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 7501 location
Breast Carcinoma
RECRUITINGNCT06885203

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention...

The goal of this research study is to learn about the effects of the BBCSI course on the quality of life of Black breast cancer survivors. A community-based and peer-led Black...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 461 location
Breast Cancer
RECRUITINGNCT02918474

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly...

This trial studies the acceptability and how well decision making tool works in supporting decision making in contralateral prophylactic mastectomy in patients with newly...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 151 location
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+20
RECRUITINGNCT07220096

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on...

The goal of this research study is to learn about: The effect of enrolling in the YOLC program on patient satisfaction with care provided, The needs of patients younger than 50...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 751 location
Lung Cancer
RECRUITINGPhase 1 / Phase 2NCT03608631

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 281 location
KRAS NP_004976.2:p.G12DMetastatic Pancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma+1
RECRUITINGNCT03460769

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to...

The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 77510 locations
Pancreatic CancerChronic PancreatitisDiabetes Mellitus Type 3c
RECRUITINGPhase 2NCT05123807

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian...

The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer

Sponsor: M.D. Anderson Cancer CenterEnrolling: 301 location
Ovarian Cancer
RECRUITINGPhase 1NCT06545682

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

To find a recommended dose of the combination of alpelisib and pembrolizumab that can be given to patients with metastatic breast cancer or melanoma.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
Melanoma (Skin Cancer)Breast CancerBrain Metastasases
RECRUITINGPhase 2NCT05546827

Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma

The goal of this clinical research study is to learn if pre-operative radiation therapy after starting immune checkpoint inhibition can help patients with sinonasal or anorectal...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
Sinonasal MelanomaAnorectal Melanoma
RECRUITINGPhase 2NCT05026983

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 351 location
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8
RECRUITINGPhase 2NCT04594187

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1683 locations
Melanoma
RECRUITINGNCT03941756

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory...

This pilot trial studies whether a procedure called lymphovenous bypass would prevent lymphedema (arm swelling) in patients with inflammatory breast cancer or non-inflammatory...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 2521 location
Anatomic Stage III Breast Cancer AJCC v8Breast Inflammatory CarcinomaLocally Advanced Breast Carcinoma+1
RECRUITINGPhase 1NCT03819296

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 8001 location
Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8+41
RECRUITINGPhase 2NCT06817720

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed...

To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
Chronic Myeloid Leukemia
RECRUITINGPhase 1 / Phase 2NCT07128381

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for...

* To find the recommended dose of axatilimab given alone and in combination with ruxolitinib in patients with MF and CMML. * To learn if axatilimab given in combination with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 661 location
Myelofibrosis (MF)Chronic Myelomonocytic Leukemia (CMML)
RECRUITINGNCT05676450

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual...

To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 5172 locations
Lymphoma
RECRUITINGPhase 2NCT05048212

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain...

A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases

Sponsor: M.D. Anderson Cancer CenterEnrolling: 201 location
Brain MetastasesRenal Cell Carcinoma
RECRUITINGPhase 2NCT02479698

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1001 location
Acquired Immunodeficiency SyndromeBK Virus InfectionHuman Immunodeficiency Virus+5
RECRUITINGPhase 2NCT05064280

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and...

This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 1041 location
Brain MetastasesTumor
RECRUITINGNCT07140757

Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 501 location
Low RiskPapillary Thyroid CancerRadiofrequency Ablation
RECRUITINGNCT07142005

Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer

To find good information about medullary thyroid cancer that is easy to understand and reliable, so researchers aim to design some new educational materials to help.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
Medullary Thyroid Cancer (MTC)Cultural Adaptation
RECRUITINGNCT04693377

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME...

This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 401 location
Castration-Resistant Prostate CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Neoplasm in the Bone+15
RECRUITINGNCT05205343

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal...

To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 204 locations
GastrostomyGastricGastroEsophageal Cancer
RECRUITINGNCT06549413

18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer

This study is being done to learn how 18F-FSPG PET/CT scan results may be related to the response to chemotherapy and radiation in patients with esophageal cancer.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 601 location
Esophageal Carcinoma
RECRUITINGNCT00991094

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 50001 location
Breast CarcinomaEsophageal CarcinomaGenitourinary System Carcinoma+6
RECRUITINGNCT06181656

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After...

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Sponsor: M.D. Anderson Cancer CenterEnrolling: 801 location
Pneumococcal VaccineEsophageal CancerLymphopenia+1
RECRUITINGPhase 1NCT03114462

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 111 location
Malignant Neoplasms of Respiratory and Intrathoracic OrgansSquamous Cell Carcinoma of the Larynx
RECRUITINGNCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 701 location
Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
RECRUITINGPhase 2NCT05776979

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

Sponsor: M.D. Anderson Cancer CenterEnrolling: 611 location
Multiple Myeloma
RECRUITINGNCT02726750

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma...

Sponsor: M.D. Anderson Cancer CenterEnrolling: 2001 location
Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma

Showing 30 of 36 trials. The remainder are accessible through individual condition pages or directly on ClinicalTrials.gov.

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does M.D. Anderson Cancer Center have on ClinicalTrials.gov?

M.D. Anderson Cancer Center has 36 clinical trials registered on the federal ClinicalTrials.gov registry, of which 36 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does M.D. Anderson Cancer Center study?

M.D. Anderson Cancer Center's registered trials cover 20 conditions on ClinicalTrials.gov, led by Melanoma (3 trials), Breast Carcinoma (2 trials), Breast Cancer (2 trials), Anatomic Stage Iii Breast Cancer Ajcc v8 (2 trials), Clinical Stage Iv Cutaneous Melanoma Ajcc v8 (2 trials). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a M.D. Anderson Cancer Center clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 36 trials tracked for M.D. Anderson Cancer Center.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

Every number on this page links back to the NIH ClinicalTrials.gov registry; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.